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SHORT COMMUNICATION
Effect of increased ART-CPT uptake on tuberculosis  
outcomes and associated factors, Burundi, 2009–2013
M. Sawadogo,1 F. Ciza,2 S. D. Nzeyimana,2 A. Shingiro,3 T. Ndikumana,2 T. Demeulenaere,1  
M. Khogali,4 M. Edginton,5,6 A. J. Reid,4 A. M. V. Kumar,7 A. D. Harries5,8
Burundi is a low-income, East African country with a population of 10 million. For the last two de-
cades it has been ravaged by civil war. Since the 1990s, 
Burundi has had a 1% prevalence rate of human im-
munodeficiency virus (HIV) infection in adults aged 
15–49 years.1 This has affected the tuberculosis (TB) 
burden, with notified cases doubling from 3326 per 
annum in 1995 to 7016 in 2012; in 2013, the national 
TB incidence rate was 128 per 100 000 population. In 
2008, HIV prevalence among newly diagnosed TB pa-
tients was 26%.2 The treatment success rate in new TB 
patients in 1995 was 45%; 10 years later it had risen to 
just over 70%.3
Cotrimoxazole preventive therapy (CPT) and an-
tiretroviral treatment (ART) are well known to reduce 
mortality in HIV-positive TB patients and to improve 
treatment success, with a synergistic benefit when 
both are taken together.4,5 The 2004 interim World 
Health Organization (WHO) TB-HIV policy advo-
cated the use of both treatments singly or together. 
The 2012 update strongly recommended 100% up-
take of CPT and ART in HIV-infected TB patients, 
both to be started as soon as possible after the initia-
tion of anti-tuberculosis treatment.6 According to the 
above WHO recommendations, ART was recom-
mended for all TB-HIV co-infected patients in Bu-
rundi in 2012.
Over the last 5 years, there has been a significant 
increase in the uptake of CPT and ART among HIV-in-
fected TB patients. While the proportion receiving 
CPT has reached 95%, i.e., near the 100% target, from 
the 47% baseline in 2009, those receiving ART reached 
only 64% in 2013 from a 2009 baseline of 32%, and 
this component remains a challenge.3 However, 
whether the increased access to CPT and ART is ac-
companied by improved treatment outcomes has not 
been formally assessed.
The objectives of this study were, among newly di-
agnosed HIV-infected TB patients, 1) to describe the 
trends in TB treatment outcomes from 2009 to 2013, 
and 2) to describe factors associated with ART uptake 
in 2012–2013.
ASPECTS OF INTEREST
This retrospective study examined the records of 
HIV-infected TB patients consecutively registered 
from January 2009 to June 2013 at 55 randomly se-
lected facilities of the country’s total 170 health fa-
cilities (health centres, regional and central hospi-
tals) where TB treatment is available. Data were 
extracted from the TB treatment registers and Epi-
Data software Version 3 was used for entry and Ver-
sion 2.2.2.183 for analysis (EpiData Association, 
Odense, Denmark). A descriptive analysis was per-
formed and χ² tests for proportions and for trend 
and comparison were calculated to show the trend 
of treatment outcomes over time. Levels of signifi-
cance were set at 5%.
Ethics approval was obtained from the Ethics Advi-
sory Group of the International Union Against Tuber-
culosis and Lung Disease, Paris, France, and the Bu-
rundi National Ethics Committee. Permission to carry 
out the study was obtained from the National Tuber-
culosis Programme (NTP).
There were 3579 HIV-infected TB patients, with a 
mean age of 39 (IQR 25–54) years. The male:female ra-
tio was 1:1; 50% had pulmonary TB and 92% were 
newly diagnosed. Three quarters had presented to and 
were being cared for at regional or central hospitals.
The trends in TB treatment outcomes are shown in 
the Figure. From 2009 to 2013, treatment success im-
proved from 71% to 80% (P  0.001). Loss to follow-up 
and transfer out decreased over the same period (P  
0.001 and P  0.05, respectively). Death rates de-
creased modestly, and remained high, at 14%, in 2013.
To examine factors associated with ART uptake, only 
data from 2012 and 2013 (1264 records) were included, 
due to the availability of data. ART uptake was worse in 
suburban areas and private for-profit hospitals (Table).
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We retrospectively examined 3579 records of human im-
munodeficiency virus infected tuberculosis (TB) patients 
diagnosed from January 2009 to June 2013 in 55 TB 
treatment facilities in Burundi, to demonstrate whether 
improvement of combined cotrimoxazole preventive 
therapy and antiretroviral therapy (ART) uptake was ac-
companied by improvement of treatment outcomes, and 
to describe associated factors. Treatment success rates in-
creased from 71% to 80% (P  0.001). While loss to fol-
low-up and transfer-out rates declined significantly, death 
rates decreased modestly, and remained high, at 14%. 
ART uptake was worse in suburban areas and private for-
profit institutions. World Health Organization targets 
could be achieved if peripheral health facilities were 
prioritised.
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DISCUSSION
This study showed that the increase in the proportion 
of HIV-infected TB patients on combined CPT/ART in 
Burundi in 2009–2013 was accompanied by a signifi-
cant improvement in NTP treatment outcomes. How-
ever, the death rate, while reduced, has remained un-
acceptably high. ART uptake was worse in suburban 
areas and private for-profit hospitals.
The strengths of this study are that programme-level 
data were used and that it included a large number of 
health facilities. Limitations relate to the difficulties of 
record review and the lack of some HIV-related data in 
TB registers. In addition, many peripheral health facili-
ties were not visited due to security issues, resulting in 
a bias towards central urban facilities with better access 
and follow-up. We did not investigate the reasons for 
the continued high death rate, as this was beyond the 
scope of the study. Finally, we were unable to docu-
ment the times when ART and CPT were started, and 
this may have a significant effect on TB case fatality. 
We were also unable to investigate a causal association 
between the increase in CPT-ART and TB outcomes. In 
addition, the relationship between CPT-ART increase 
and TB outcomes was only demonstrated for 2 years.
Treatment outcomes in this study were similar to 
those in Uganda, where the integration of TB and HIV 
care led to improved TB treatment outcomes and ear-
lier ART initiation.7 Such results support the rollout of 
a fully integrated TB-HIV service delivery model 
throughout high-prevalence TB and HIV settings.
Although the death rate among TB patients decreased 
modestly between 2010 and 2013, it remained high, at 
14%. Addressing diagnostic delays and initiating ART 
soon after starting anti-tuberculosis treatment may be 
ways forward.8 The causes of death also need to be ex-
amined more closely, as well as the effect of increased 
CPT-ART uptake on reductions in loss to follow-up and 
transfer-out.
In a rural district in Malawi, ART uptake among TB 
patients was low and associated with the costs of trans-
port to a centralised hospital site providing ART.9 Our 
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TABLE Factors associated with ART uptake among 
HIV-positive TB patients in Burundi, January 2012–June 2013
Category
ART uptake
n (%) P value
Age group, years (n = 1264)
 1–14 38 (83) 0.19
 15–24 94 (73)
 25–54 753 (78)
 55 87 (71)
Sex (n = 1263)
 Male 551 (77) 0.81
 Female 420 (77)
Type of TB (n = 1264)
 PTB 497 (77) 0.81
 EPTB 475 (76)
Site of TB (n = 1264)
 Pulmonary 497 (77) 0.65
 Pleural 107 (79)
 Pericardial 33 (75)
 Peritoneal 30 (75)
 Meningeal 36 (78)
 Lymph and node 42 (78)
 Bones and joints 30 (86)
 Genitourinary 8 (89)
 Miliary or disseminated 94 (78)
 Not recorded 95 (70)
Health service attendance  
(n = 1264)
 Public 875 (77) 0.0001
 Private not-for-profit 79 (86)
 Private for-profit 18 (49)
Availability of ART at the same HC 
(n = 1264)
 ART not available 8 (79) 0.58
 ART available 889 (77)
Examinee’s residence (n = 1263)
 Rural area 216 (79) 0.0001
 Suburban area 51 (54)
 Urban area 704 (79)
ART = antiretroviral treatment; HIV = human immunodeficiency virus; 
TB = tuberculosis; PTB = pulmonary TB; EPTB = extra-pulmonary TB; 
HC = health centre.
FIGURE Trend of treatment outcomes for all TB patients in Burundi who were HIV-positive, 2009–2013. * Success = 
cured or treatment completed. †Data for year 2013 year concerns the 6 months (from 1 January to 30 June) for which 
treatment outcomes were available. LTFU = lost to follow-up. TB = tuberculosis; HIV = human immunodeficiency virus.
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study demonstrates the need to decentralise ART from central to 
peripheral facilities closer to the patients’ homes as an essential 
step towards better coverage, with more attention paid to suburban 
areas, where poverty, unemployment and overcrowding are sources 
of inequality. Future research should incorporate qualitative re-
search methods to assess precise reasons for not receiving ART.
In conclusion, this study showed that the improvement in 
ART and CPT uptake was accompanied by the improvement of TB 
treatment outcomes in Burundi. With more efforts to decentralise 
care, the WHO targets may be achieved. New approaches may be 
required to address the unacceptably high death rates.
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Une étude rétrospective conduite de janvier 2009 à juin 2013 au 
Burundi chez 3579 patients co-infectées par la tuberculose (TB) et le 
virus de l’immunodéficience humaine dans 55 centres de diagnostic 
et de traitement de la TB, décrit l’évolution des résultats de 
traitement antirétroviral (ART) et cotrimoxazole et apprécie les 
facteurs liés à l’ART. La proportion des succès au traitement a 
augmenté de 71% à 80% (P  0,001). Tandis que les taux de perdus 
de vue et de transferts ont baissé significativement, celui des décès 
n’a baissé que modestement, tout en restant élevée, à 14%. La 
couverture en ART est plus faible dans les centres de santé 
périphériques et dans ceux relevant du privé non lucratif. Les 
objectifs de l’Organisation Mondiale de la Santé pourraient être 
atteints si les districts sanitaires ruraux étaient inclus dans la 
fourniture des soins.
En el presente estudio se analizaron 3579 registros de pacientes 
aquejados de coinfección por el virus de la inmunodeficiencia 
humana (VIH) y la tuberculosis (TB) en Burundi de enero del 2009 
a junio del 2013, provenientes de 55 establecimientos de 
tratamiento de la TB, con el objeto de investigar si al aumentar la 
aceptación del tratamiento preventivo con cotrimoxazol en 
asociación con el tratamiento antirretrovírico (ART) se mejoraban 
los desenlaces terapéuticos y también se describieron los factores 
que se asociaban con esta situación. Las tasas de éxito terapéutico 
aumentaron de un 71% a un 80% (P  0,001). Aunque las tasas de 
pérdida durante el seguimiento y de remisión a otros 
establecimientos disminuyeron de manera significativa, la 
disminución de las tasas de mortalidad fue leve y permanecieron en 
un nivel alto de 14%. La aceptación del ART fue más deficiente en 
las zonas suburbanas y en los establecimientos privados con ánimo 
de lucro. Sería posible cumplir con las metas de la Organización 
Mundial de la Salud si se da prioridad a los establecimientos 
sanitarios periféricos.
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